ID   KY-ADR1
AC   CVCL_Z939
DR   Wikidata; Q54900768
RX   PubMed=7934146;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Ara-C).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Derived from site: In situ; Brain, meninges; UBERON=UBERON_0010743.
DI   NCIt; C7463; Acute myelomonocytic leukemia
DI   ORDO; Orphanet_517; Acute myelomonocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_W294 ! KY-Ra
SX   Male
AG   28Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 29-06-23; Version: 9
//
RX   PubMed=7934146; DOI=10.1016/0145-2126(94)90071-X;
RA   Fukuda T., Kakihara T., Kamishima T., Ohnishi Y., Naito M., Kishi K.,
RA   Shibata A., Tsuruo T.;
RT   "Characterization of newly established adriamycin resistant human
RT   leukemic cell lines (KY-ADR1 and KY-ADR2).";
RL   Leuk. Res. 18:709-715(1994).
//